The 90‑day clock is not your launch clock
If you’re still building England launch plans around “NICE published + 90 days”, you’re not forecasting access. You’re writing a retrospective. We’ve discussed that for most medicines, 24 months is closer to the real implementation period and that follow-on medicines tend to implement faster than new innovations. But there is a third way NICE use to implement faster.
Because the Innovative Medicines Fund (IMF) has become the most under‑read, over‑assumed part of the NICE‑to‑NHS pathway. Not because people don’t know it exists. Because too many people still treat it as “that fund for uncertain evidence”.
That’s only half the story.
The IMF is also being used as a bridge: interim funding for medicines NICE has already recommended for routine commissioning. It’s not the headline mechanism. It’s the mechanism that changes your first prescribing date, your implementation plan, your internal narrative of what “launch” even means, and the NHS’s expectations of how quickly you can make the product real.
If you’re a market access lead on a specialised medicine, this is the bit you can’t afford to treat as background noise.
What “IMF bridging” actually is (and what it isn’t)
Start with a clean distinction. The IMF has two modes that get mashed together in conversations and, frankly, in too many internal decks.
Mode 1 is managed access. This is the classic story: NICE can’t recommend routine use because of unresolved uncertainty, so the NHS funds time‑limited access while more data is generated.
Mode 2 is interim funding. This is the bridge. NICE can recommend routine commissioning. But NHS England uses the IMF as discretionary early funding to cover the implementation runway, then switches the medicine into routine budgets when the implementation window closes.
Bridging is not a consolation prize. It is not “NICE wasn’t sure”. It’s a deliberate use of a ring fenced early‑access budget to make implementation happen without waiting for the system to move at its natural pace.
That should make launch teams uncomfortable, because it means the system can start the access clock earlier than you’re used to.
The three periods in play (and why your dashboards should show all three)
You don’t have “one date” to manage. You have three periods, each with different consequences.
First, Final Draft Guidance (FDG). This is the point the appraisal has effectively landed and the appeal window is live. Under IMF principles, interim funding can be brought forward from draft positive final guidance, in some cases by up to five months.
Second, final TA publication. This is the date everyone tracks. It’s also the date too many teams treat as “Day 0”, even though the operational system has already started moving.
Third, the implementation window. Most people call this “the 90‑day rule”. It’s the legal baseline. But it is not always 90. Cost‑comparison technology appraisals can run on a 30‑day implementation agreement. And the IMF guidance explicitly contemplates that reality.
Here’s the punchline: IMF bridging sits across these periods. It can start at FDG. It can start after final publication. It ends when the implementation window closes and funding switches into routine budgets.
If your launch plan doesn’t explicitly model FDG to TA publication to implementation window end, you are flying on one instrument.
Garadacimab is a neat example because the dates spell it out
Garadacimab (Andembry) is a clean bridging case because you can read the story straight off the national IMF list.
NICE TA1101 was published on 08 October 2025. The FDG was published on 18 September 2025.
On the NHS England national IMF list, garadacimab shows an IMF start date of 23 October 2025 and a routine commissioning date of 06 January 2026.
That 06 January date is exactly 90 days after TA publication. In other words: routine budgets switched on the statutory deadline, as you’d expect.
So why bridge at all?
Because access isn’t just a legal obligation. It’s an implementation exercise: commissioning criteria, Blueteq, centre readiness, treatment pathway positioning, home care or supply arrangements, finance and contracting mechanics. The IMF principles are explicit that interim funding exists because some medicines need time for clinical, financial and logistical pathway change, and interim funding can provide a path to full implementation.
Notice something else: garadacimab’s IMF start date is after the final TA publication, not at FDG. That matters. It proves a point many teams miss: interim funding is not an automatic “FDG trigger”. It is an offer, with prerequisites, that becomes real when the machine is ready and the commercial/governance conditions are met.
If your internal story is “IMF bridging starts at FDG”, garadacimab is the counterexample. If your internal story is “IMF bridging doesn’t matter because routine commissioning starts at day 90 anyway”, garadacimab is also the counterexample. Bridging changes what happens inside the window.
This has happened before. Repeatedly. Across therapy areas.
If you want to see whether bridging is “real” or “rare”, stop arguing in the abstract. Look at the IMF list section that tracks medicines moved into routine commissioning. It reads like a map of where the NHS finds implementation hard enough to justify a bridge.
You see rare and specialist immunology, haematology/transplant complications, neurology, hepatology/infectious disease, ultra‑rare metabolic disease, and supportive care adjacent to oncology. In other words: specialised pathways with governance and delivery complexity.
A few examples make the pattern obvious.
Belumosudil (TA949) starts IMF funding on 21 December 2023 and moves into routine commissioning on 07 May 2024. That the IMF start aligns with the FDG publication date, not the final TA publication date.
Fenfluramine (TA1050) starts IMF funding on 20 February 2025 and moves into routine commissioning on 24 June 2025. Again, IMF starts aligning with FDG.
Benralizumab for EGPA (listed with NICE ID6266 on the IMF list) starts IMF funding on 14 August 2025 and moves into routine commissioning on 02 December 2025. Same pattern.
And then you have the example that quietly exposes another market access blind spot: ublituximab (TA1025). It starts IMF funding on 29 November 2024 and moves into routine commissioning on 17 January 2025. That’s not 90 days after TA publication. It’s 30 days — because ublituximab was recommended through NICE’s cost‑comparison process, and NHS England and ICBs agreed a 30‑day implementation timeframe. NICE spells that out in the guidance itself.
If your team talks about “the 90‑day rule” as if it’s universal, you’re going to mis‑forecast routine commissioning dates for exactly the kinds of products that are most likely to matter commercially.
What kinds of products get bridged
Here’s the uncomfortable truth: bridging tends to show up where market access work has to be operational, not rhetorical.
Bridging is most plausible when the medicine sits in or touches a prescribed specialised service, and when implementation requires more than “add to formulary”.
That often correlates with:
A tightly defined eligible population is usually rare or specialist.
High cost and high governance: Blueteq criteria, specialist centre prescribing, MDT processes, national commissioning expectations.
Delivery and pathway change: switching protocols, monitoring regimes, home care logistics, infusion capacity, and diagnostics readiness.
And a manufacturer willing to accept the IMF’s financial control terms. Interim funding is not “free early access”. It is an early access under a control mechanism.
This is where I’ll be provocative: too many launch teams treat IMF bridging as “nice, if it happens”. NHS England treats it as “possible, if you’re ready and you accept the rules”. Those are not the same posture.
The hidden price of early funding: ECM, service planning, and credibility
The IMF principles are unambiguous: interim funding is discretionary, and companies need to have marketing authorisation, a responsible price (enough to secure a routine recommendation), and provide complete and timely information to support service planning. They also need to sign up to the IMF expenditure control mechanism (ECM). If they don’t, interim funding isn’t available.
That is the part that doesn’t make it into most internal launch narratives.
If you’re launching, bridging is not just a date shift. It’s an implicit contract: you get earlier funding, and the system gets predictability, control, and the information it needs to implement.
If you want the benefits of being “live” earlier, you have to be operationally ready earlier. That sounds obvious. In practice, it’s the thing most teams under‑resource until after TA publication, then wonder why uptake lags even when funding exists.
What I would change in a launch plan tomorrow morning
If I was running market access for a specialised launch in England, I’d make three changes immediately.
First, I’d stop treating TA publication as “Day 0”. I’d treat FDG as the first genuine access signal. Not because interim funding always starts at FDG, but because it can — and because the system’s readiness work starts before your celebratory internal email.
Second, I’d model the implementation window properly. Default 90 days, yes. But explicitly check whether the topic is a cost‑comparison appraisal or otherwise has an agreed shorter implementation period. Ublituximab is your warning sign. The date can compress, and the IMF mechanism explicitly accommodates that.
Third, I’d build a service‑planning pack that is “FDG‑ready”, not “post‑publication‑ready”. Commissioning criteria translation, centre pathway mapping, Blueteq readiness, supply/homecare mechanics, and the operational questions providers will ask in the first call after the decision signal. If you can’t answer those questions early, you’re not accelerating access; you’re simply accelerating confusion.
This is the part that will annoy some people: market access teams often say “implementation is the NHS’s job”. Interim funding is the NHS saying, “Fine, but we’re starting the clock earlier”. You don’t get to outsource readiness and still claim you’re running an accelerated launch.
The simple conclusion
IMF bridging is not an edge case. It is a repeatable pattern that shows up in precisely the kinds of specialised launches that are hardest to implement and easiest to mis‑forecast.
If you’re a market access lead, it should change how you read the calendar, how you define “launch”, and how early you demand cross‑functional readiness.
The question isn’t “will we get NICE”.
It’s “when does the access clock actually start, what is the real implementation window, and are we ready to operate inside it?”.
If you can’t answer that before TA publication, you’re already behind.